ouabain has been researched along with Ventricular Dysfunction, Left in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clanachan, AS; Lopaschuk, GD; Wang, L | 1 |
| Brixius, K; Hambarchian, N; Lu, R; Müller-Ehmsen, J; Schwinger, RH | 1 |
| Lloyd, S; Mattson, JP; Musch, TI; Pickar, JG | 1 |
| Casarotto, D; Ferrari, M; Magnolfi, G; Padrini, R; Panfili, M; Piovan, D | 1 |
| Hideg, K; Kalai, T; Kuppusamy, P; Li, H; Xu, KY; Zhou, L; Zweier, JL | 1 |
| Hageman, KS; Musch, TI; Pickar, JG; Wolfram, S | 1 |
6 other study(ies) available for ouabain and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
H(2)O(2)-induced left ventricular dysfunction in isolated working rat hearts is independent of calcium accumulation.
Topics: Animals; Anti-Arrhythmia Agents; Benzothiazoles; Calcium; Calcium Channel Blockers; Cardiotonic Agents; Cnidarian Venoms; Hydrogen Peroxide; Ion Transport; Lidocaine; Male; Myocardial Reperfusion Injury; Myocardium; Organ Culture Techniques; Ouabain; Oxidants; Piperidines; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left | 2008 |
Ouabain increases myofibrillar Ca2+ sensitivity but does not influence the Ca2+ release in human skinned fibres.
Topics: Adult; Caffeine; Calcium; Female; Humans; In Vitro Techniques; Isometric Contraction; Male; Middle Aged; Muscle Fibers, Skeletal; Myocardial Contraction; Myocardium; Myofibrils; Ouabain; Sarcoplasmic Reticulum; Sodium-Potassium-Exchanging ATPase; Stimulation, Chemical; Time Factors; Ventricular Dysfunction, Left | 2004 |
Decreased [3H]ouabain binding sites in skeletal muscle of rats with chronic heart failure.
Topics: Animals; Binding Sites; Chronic Disease; Female; Heart Failure; Locomotion; Muscle Contraction; Muscle, Skeletal; Myocardial Infarction; Ouabain; Rats; Rats, Wistar; Sodium Channels; Sodium-Potassium-Exchanging ATPase; Ventricular Dysfunction, Left | 1997 |
Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium.
Topics: Aging; Cardiomyopathy, Dilated; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; In Vitro Techniques; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Myocardium; Ouabain; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 1999 |
A pyrroline derivative of mexiletine offers marked protection against ischemia/reperfusion-induced myocardial contractile dysfunction.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Binding, Competitive; Coronary Circulation; Dose-Response Relationship, Drug; Female; Hydroxyl Radical; Mexiletine; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Ouabain; Oxidation-Reduction; Pyrroles; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Ventricular Dysfunction, Left; Ventricular Pressure | 2000 |
Skeletal muscle ouabain binding sites are reduced in rats with chronic heart failure.
Topics: Animals; Binding Sites; Cardiac Output, Low; Chronic Disease; Fatigue; Female; Motor Activity; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Osmolar Concentration; Ouabain; Oxygen Consumption; Physical Endurance; Rats; Rats, Wistar; Severity of Illness Index; Time Factors; Ventricular Dysfunction, Left | 2002 |